Search research articles
Contact Us
Filters
Showing results (101-110 of 143) with videos related to
Page
of 15
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 9, 2024
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48
Tarik Asselah, Pietro Lampertico, Soo Aleman, et al.
Molecular Therapy. Advances
|
May 15, 2026
A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations
Soo Aleman, Gustaf Ahlén, Jingyi Yan, et al.
JHEP Reports : Innovation in Hepatology
|
May 1, 2026
Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B
Marte Holmberg, Annika Niehrs, Olav Dalgard, et al.
Science Immunology
|
December 8, 2023
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Curtis Cai, Yu Gao, Sarah Adamo, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 14, 2023
Functional SARS-CoV-2 cross-reactive CD4<sup>+</sup> T cells established in early childhood decline with age
Marion Humbert, Anna Olofsson, David Wullimann, et al.
Molecular Medicine (Cambridge, Mass.)
|
May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
Caroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Ebiomedicine
|
July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Puran Chen, Peter Bergman, Ola Blennow, et al.
Clinical & Translational Immunology
|
December 21, 2020
Innate lymphoid cell composition associates with COVID-19 disease severity
Marina García, Efthymia Kokkinou, Anna Carrasco García, et al.
Journal of Hepatology
|
April 29, 2023
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Julius Hollnberger, Yang Liu, Simin Xu, et al.
Ebiomedicine
|
May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity
Puran Chen, Peter Bergman, Ola Blennow, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 143) with videos related to
Sort By:
Page
of 15
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 9, 2024
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48
Tarik Asselah, Pietro Lampertico, Soo Aleman, et al.
Molecular Therapy. Advances
|
May 15, 2026
A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations
Soo Aleman, Gustaf Ahlén, Jingyi Yan, et al.
JHEP Reports : Innovation in Hepatology
|
May 1, 2026
Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B
Marte Holmberg, Annika Niehrs, Olav Dalgard, et al.
Science Immunology
|
December 8, 2023
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Curtis Cai, Yu Gao, Sarah Adamo, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 14, 2023
Functional SARS-CoV-2 cross-reactive CD4<sup>+</sup> T cells established in early childhood decline with age
Marion Humbert, Anna Olofsson, David Wullimann, et al.
Molecular Medicine (Cambridge, Mass.)
|
May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
Caroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Ebiomedicine
|
July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Puran Chen, Peter Bergman, Ola Blennow, et al.
Clinical & Translational Immunology
|
December 21, 2020
Innate lymphoid cell composition associates with COVID-19 disease severity
Marina García, Efthymia Kokkinou, Anna Carrasco García, et al.
Journal of Hepatology
|
April 29, 2023
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Julius Hollnberger, Yang Liu, Simin Xu, et al.
Ebiomedicine
|
May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity
Puran Chen, Peter Bergman, Ola Blennow, et al.
Page
of 15